Karaye, Ibraheem M.
Ludeke, Can Martin
Eikermann, Greta Muriel
Eyth, Annika
Ramishvili, Tina
Azimaraghi, Omid
Rudolph, Maira
Aber, Nicole
Bhasin, Vikram
Bastien, Alexandra
Eikermann, Matthias
Article History
Accepted: 17 April 2024
First Online: 6 May 2024
Declarations
:
: Matthias Eikermann has received unrestricted funds from philanthropic donors Jeffrey and Judy Buzen, as well as grants from Merck & Co. not related to this study. He also holds a patent describing the value of acyclic CB[n]-type compounds for reversing the effects of drugs of abuse (Patent number: 9956229).All other investigators declare no conflicts of interest.